BCAX

$23.63-$1.00 (-4.06%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$1.6B

66M shares

52-week range

$10.30 – $30.99

64% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change+$0.22

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-3.49	$-4.16–$-2.57	—	11
2027	$0	—	$-3.70	$-4.40–$-2.74	—	10
2028	$42M	—	$-3.53	$-4.39–$-2.42	—	10
2029	$197M	+375.3%	$-2.49	$-2.49–$-2.49	—	4

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.82	$-0.82	-0.0%
2026-05-11	$-0.64	$-0.93	-45.3%
2026-03-26	$-0.72	$-0.68	+5.6%
2025-11-10	$-0.55	$-0.67	-21.8%
2025-08-12	$-0.54	$-0.50	+7.4%
2025-05-13	$-0.40	$-0.68	-70.0%
2025-03-27	$-0.31	$-0.39	-25.8%
2024-11-12	$-0.46

DCF fair valuemodel estimate

Intrinsic value

$1.60

Price

$23.63

Implied downside

-93%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
BCAXBicara Therapeutics Inc. Common Stock	$23.63	-4.06%	$1.6B	—
EYPTEyePoint Pharmaceuticals, Inc.	$13.48	-0.37%	$1.1B	—
FTREFortrea Holdings Inc.	$17.82	-2.78%	$1.7B	—
KURAKura Oncology, Inc.	$10.09	+1.51%	$896M	—
MRVIMaravai LifeSciences Holdings, Inc.	$5.78

Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

www.bicara.com

Employees: 103
IPO / List date: Sep 13, 2024
HQ: BOSTON, MA

Held by traders on TradeandTell

No one on the platform currently holds BCAX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in BCAX as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded BCAX yet.

$BCAX chatter on StockTwits

Quantumup@Quantumup1d
BTIG y'day⬆️ $BCAX's PT to $39 and reiterated Buy after BCAX reported 2Q26 earnings. MRUS - $GMAB $MRK LLY AZN INCY Here's what BTIG said: https://x.com/Quantumup1/status/2087521829992681535?s=20
View on StockTwits ↗
Florestan@FlorestanBullish2d
$BCAX Down 15% on a couple of promotions is wild 🤪
View on StockTwits ↗
Stocktwits News@StocktwitsNews2d
BCAX Q2 2026 Earnings Summary $BCAX https://stocktwits.com/news/earnings/ai summaries/bcax-q2-2026-earnings-summary/cZoNde0RJXf
View on StockTwits ↗
M@justiceforb_852d
$BCAX added. Trial data in mid-2027 for P3 is a while away (mid 2027) but there will be an interim update by end of this year for ficerafusp in CRC.
View on StockTwits ↗
MarketBeat Earnings@EarningsInsider2d
https://www.marketbeat.com/earnings/reports/2026-8-11-bicara-therapeutics-inc-stock/ $BCAX Bicara Therapeutics Earnings Transcript
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarnings2d
$BCAX Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.82 down -64.00% YoY
View on StockTwits ↗
Victor Jade@vu_jadeBullish3d
$BCAX great entry area
View on StockTwits ↗
ASE@SilverEagleBullish3d
$BCAX 👀
View on StockTwits ↗
M@justiceforb_85Aug 6
$BCAX will be very interested in data readout for ficerafusp in CRC later this year.
View on StockTwits ↗
Quantumup@QuantumupAug 3
Wells Fargo🏁 $PYXS Overweight-$12 and said -- We think the Street under-appreciates two things: dose capping likely addresses concerns on MICVO'S safety, and the 2L+ HNSCC oppty is wide open as EGFR bispecifics take over 1L. $MRK $BCAX GILD BGNE Here's what else Wells Fargo said in its initiation report: https://x.com/Quantumup1/status/2084267889251520559?s=20
View on StockTwits ↗
Dirkdiggler@vvvvvvrebel89130Jul 31
$BCAX halted
View on StockTwits ↗
StockConsultant.com@StockConsultantJul 23
$BCAX Bicara Therapeutics stock watch, nice trend with a pullback to 27.66 and good trade quality at https://stockconsultant.com/?BCAX Long Trade Target 1: 32.15 Profit: 15% Stop/Trailing Stop: 26.76 Loss: 4.3% P/L ratio: 3.5 : 1 - Good Target 2: 33.51 Profit: 19.8% P/L ratio: 4.6 : 1 - Excellent Extreme rally BULLISH [Positioning] at support [Timing] Mild bullish 3 day candlestick pattern. BEARISH [Positioning] Intermediate trend bearish, Unsustainable uptrend, may turn sideways.
View on StockTwits ↗
Biotech Beast@Biotech_BeastJul 15
Key head and neck readouts from, $PYXS's Micvo and $GMAB's petosemtamab ahead in H2'26. An update from $BCAX is out of the way for now I think. I took a look at PYXS in more detail. BVF LP is onboard as an investor with the recent raise. https://seekingalpha.com/article/4921917-pyxis-oncology-the-market-might-have-already-ruled-on-micvotabart-pelidotin
View on StockTwits ↗
Mr. Layne@LaynesterBullishJul 8
$BRBR $VKTX $IMMX $RARE $BCAX Past 3wk price performance +50%, +40%, +40%, +40%, +40% respectively. The HEALTCARE BUY (and the INSURANCE sector BUY) looks to be FADING, as a caution. Set a stop. Good skills to all of us slaves around the world.
View on StockTwits ↗
Florestan@FlorestanBullishJul 8
$BCAX no one talks about the greatest CR profile in HNSCC 1st line? I love it.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.